[뉴스토마토 동지훈 기자] It is evaluated that the conquest of dementia, which was considered an incurable disease, has entered the field of visibility. This is because products that can diagnose Alzheimer’s have been developed and are being used, and the development of treatments is also accelerating.
According to the industry on the 31st, domestic licensed products that can diagnose Alzheimer’s disease include Futurechem’s Alzavu, GE Healthcare’s Bizamil, and Eli Lilly’s Amivid.
These products diagnose disease through the deposition of beta-amyloid protein found in the brain of Alzheimer’s patients. Beta-amyloid is one of the proteins mainly found in patients with mild cognitive impairment, which is an early stage of Alzheimer’s. It is known that when beta-amyloid begins to attach to cells, the brain size decreases and cognitive function declines. This led to the hypothesis that beta-amyloid is the cause of Alzheimer’s.
Beta-amyloid is a major factor in Alzheimer’s diagnosis products, but it is neglected in the treatment area. Aduhelm, which was approved as the world’s first Alzheimer’s treatment last year, is a representative example.
Aduhelm is a drug that targets beta-amyloid. The U.S. Food and Drug Administration (FDA) granted approval for the phase 4 clinical trial after marketing despite the low efficacy shown in the phase 3 clinical trial. On the other hand, in Europe, developers Biogen and Eisai decided to voluntarily withdraw their license application.
Although the expansion of the use of arduhelm has been stopped, the development of therapeutic agents is accelerating in each country.
A total of 143 new drug candidates for Alzheimer’s were discovered this year, and 172 clinical trials were conducted. (Photo = Aribio)
According to the clinical trial information site operated by the National Institutes of Health (NIH), a total of 143 new Alzheimer’s drug candidates were discovered as of this year, and 172 clinical trials were conducted. 31 candidates for phase 3 clinical trials closest to commercialization were counted.
Unlike Aduhelm, which was developed as a single target treatment for beta-amyloid, these candidate substances have several types of targets, such as cause control agents, symptom control agents, and cognitive enhancing drugs.
Industry analysts say that the commercialization of diagnostic products and the development of therapeutics can lead to fundamental Alzheimer’s treatment.
An industry official said, “Although Aduhelm’s European approval is stranded, it is meaningful in that it is the world’s first Alzheimer’s treatment approval. did.
The official also predicted, “If the focus has been on alleviating the symptoms of Alzheimer’s, the flow of identifying the cause of the disease and treating it will develop in the future.”
Another official said, “It’s the same now, but in the past, there was a lot of perception that it was difficult to treat dementia when it was diagnosed. not,” he said.
He added, “The key in the future is the speed of treatment development.” He added, “There is a possibility that the time (from diagnosis to treatment of Alzheimer’s disease) may be shortened depending on the results of clinical trials.”
By Dong Ji-hoon, staff reporter firstname.lastname@example.org
ⓒ Delicious News Tomato, reprinted without permission – redistribution prohibited